Lindus Health, a London-based startup backed by Peter Thiel, has secured $55 million in a Series B funding round led by Balderton Capital. The company, founded in 2021 and led by co-founder Meri Beckwith, aims to overhaul the 'broken' clinical trial industry. Lindus Health has developed a comprehensive platform that automates the entire process of conducting clinical trials, positioning itself as an 'anti-CRO' alternative to traditional contract research organizations (CROs). The platform has been used for trials across Europe and the U.S., targeting conditions such as asthma, acne, chronic fatigue syndrome, diabetes, hypertension, weight management, and social anxiety. The funding will support the company's expansion into the U.S., where it plans to relocate its global headquarters, and enhance its capabilities in more complex trial types and real-time data analysis using artificial intelligence.